Intranasal drugs possibilities in the treatment of patients with rhinitis medicamentosa

Abstract

Introduction. The article presents the physiology of nasal breathing, as well as the problem of nasal obstruction and the mechanisms of its development. Topical issues of rhinitis medicamentosa are discussed, based on the pathogenic links of this condition. It has been established that there is no single treatment regimen for rhinitis medicamentosa at the moment.Objectives. To evaluate the effectiveness and safety of the use of intranasal drugs in patients with medical rhinitis.Materials and methods. A comparative study of the clinical use of the complex preparation Frinozol®, the active substances of which are the decongestant phenylephrine and the antihistamine drug cetirizine, intranasal glucocorticosteroid Nosefrin®, as well as their combinations, was carried out in patients with rhinitis medicamentosa.Results. The results showed that the use of Frinozol®, Nozefrin®, as well as a combination of these drugs leads to a decrease in the frequency of use of nasal decongestants, and in a larger percentage of cases or to the complete cessation of their use by patients with drug-induced rhinitis. The combination of Frinozol – Nozefrin is somewhat more effective. However, a number of patients resume the use of nasal decongestants after some time, which leads to the need for additional courses of conservative therapy. In the course of the observational study, we noted excellent and good tolerability of the drugs, and patient satisfaction with the treatment in all groups.Conclusions. The problem of drug-induced rhinitis remains unresolved, which is why the search for optimal and effective schemes for the conservative treatment of this disease continues. The use of intranasal glucocorticosteroids and topical antihistamines can significantly reduce the frequency of use of nasal decongestants, or completely abandon their use.